Sanofi

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Regeneron Pharmaceuticals

Dupixent ® (dupilumab) application for treatment of chronic spontaneous urticaria (CSU) in adults and adolescents accepted for FDA review

Press Release: Dupixent® (dupilumab) application for treatment of chronic spontaneous urticaria (CSU) in adults and adolescents accepted for FDA review

DuPont de Nemours

Ecopetrol

Emerson Electric

Roper Technologies

Stellantis N.V. 

United Microelectronics

When the game's on the line, sometimes you need to call up your most experienced players, which segues into this discussion of blue-chip stocks to buy. Any sports fan realizes that age comes for every athlete, including the great Tom Brady.

7 Blue-Chip Stocks to Buy for Quality-Focused Investors

Altuviiio is indicated to prevent and control bleeding episodes in hemophilia patients. In 2022, Sanofi saw business EPS grow more than 17% year over year.

Sanofi Could Be on a Roll With a Strong Performance and Its Latest FDA Approval

Completed XTEND-Kids P hase 3 study strengthens potential of ALTUVIIIO™ to red e fin e expectations for treatment of children

Press Release: Completed XTEND-Kids Phase 3 study strengthens potential of ALTUVIIIOTM to redefine expectations for treatment of children

Advanced Semiconductor Engineering

Concrete Pumping Holdings

JinkoSolar Holding

Universal Forest Products

We have screened value stocks JKS, UFPI, ASX, BBCP and SNY based on the EV-to-EBITDA ratio, which offers a clearer picture of valuation and earnings potential.

5 Stocks With Amazingly Low EV-to-EBITDA Ratios to Snap Up

FDA approves once-weekly ALTUVIIIO™, a new class of factor VIII therapy for hemophilia A that offers significant bleed protection. This positive event triggers impairment reversal, impacting 2022 IFRS net income; no change on business net income (non-IFRS)

ALTUVIIIO™ approved by the U.S. FDA: this positive event triggers impairment reversal, positively impacting 2022 IFRS net income; no change on business net income (non-IFRS)

New Phase 3 data presented at WORLDSymposium ™ reinforce Nexviazyme ® ( avalg lu cosidase alfa) as potential new standard of care for all people living with late-onset Pompe disease

Press release: New Phase 3 data presented at WORLDSymposium™ reinforce Nexviazyme® (avalglucosidase alfa) as potential new standard of care for all people living with late-onset Pompe disease

Sanofi gets FDA approval for hemophilia drug

FDA approves once-weekly ALTUVIIIO ™ , a new class of factor VIII therapy for hemophilia A that offers significant bleed protection

Press Release: FDA approves once-weekly ALTUVIIIO™, a new class of factor VIII therapy for hemophilia A that offers significant bleed protection

Novo Nordisk

SNY vs. NVO: Which Stock Is the Better Value Option?

SNY vs. NVO: Which Stock Should Value Investors Buy Now?

AbbVie

Alvotech SA

Amgen

Bristol-Myers

Coherus BioSciences

Cigna

CVS Health

Fresenius Medical Care

GlaxoSmithKline

Johnson & Johnson

Merck

Novartis

Organon & Co

Pfizer

Roche Holding AG

Teva Pharmaceutical

Viatris

It's among the prohibitively expensive biologic pharmaceuticals being replaced by cheaper “biosimilar” copycats. Relief is on the way for patients who need Humira, a product made by AbbVie.

Competition Coming For AbbVie's Blockbuster Humira

Ambev

Bayer AG

Anheuser-Busch InBev

Experian PLC

Novozymes A/S

Reckitt Benckiser Group PLC

Tencent Holdings Limited

Taiwan Semiconductor Manufacturing

Our 3-step process focuses on wide-moat stocks (as per Morningstar's rating). We are only interested in those targets that are attractively valued in historical comparison.

International Wide-Moat Stocks On Sale - The February 2023 Heat Map

Paris, February 13, 2023. Sanofi announced today that Dr. John Reed, its Global Head of R&D, will be leaving the company to pursue a new opportunity outside Sanofi. The company warmly thanks Dr. Reed for his leadership over these last years. Since joining Sanofi in 2018, John has laid the foundation for the company's R&D transformation. He helped reshape Sanofi's discovery and development of therapeutics, focusing efforts on first and best in class medicines that have the potential to transform the practice of medicine and improve the lives of people with serious diseases, whilst managing the integration and development of new technology platforms and partnerships, and driving R&D productivity.

Press Release: Sanofi announces change in R&D leadership

The stock price of Sanofi (NASDAQ: SNY) fell by 2.58% in the most recent trading session. This is why.

SNY Stock: 2.58% Decrease Explained

Sanofi SA (NASDAQ:SNY ) Q4 2022 Results Conference Call February 3, 2023 8:00 AM ET Company Participants Eva Schaefer-Jansen - Head, IR Paul Hudson - CEO Bill Sibold - EVP, Specialty Care and President, North America Thomas Triomphe - EVP, Vaccines Olivier Charmeil - EVP, General Medicines Julie Van Ongevalle - EVP, Consumer Healthcare Jean-Baptiste de Chatillon - EVP and CFO John Reed - EVP and Global Head, R&D Conference Call Participants Graham Parry - BofA Peter Welford - Jefferies Richard Vosser - JPMorgan Mark Purcell - Morgan Stanley Luisa Hector - Berenberg Tim Anderson - Wolfe Research Peter Verdult - Citi Richard Vosser - JPMorgan Steve Scala - Cowen Matthew Weston - Credit Suisse Keyur Parekh - Goldman Sachs Richard Parkes - Exane Eva Schaefer-Jansen [Call Starts Abruptly] find the slides to this earnings call on the Investors page of our website at sanofi.com. Moving to slide 3, I would like to remind you that information presented in this call contains forward-looking statements that involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially.

Sanofi SA (SNY) Q4 2022 Earnings Call Transcript

Sanofi (SNY) misses fourth-quarter estimates for earnings and sales. Higher sales of Dupixent and other specialty medicines were offset by a decline in vaccine sales.

Sanofi (SNY) Q4 Earnings Miss Estimates, Vaccine Sales Weak

Regeneron Pharma beat quarterly forecasts Friday, but its partner Sanofi posted a mixed report. Regeneron stock rose as SNY stock toppled.

Regeneron Pharma Outplays Fourth-Quarter Decline, But Sanofi Stock Topples

Sanofi SA on Friday posted rising earnings and sales for the fourth quarter and said it expects its earnings per share to grow in 2023.

Sanofi profit narrowly beats forecasts, sees stronger earnings growth in 2023

Strong sales performance and double digit EPS growth marking the achievement of the 2022 profitability milestone

Press Release : Strong sales performance and double digit EPS growth marking the achievement of the 2022 profitability milestone

SNY or NVO: Which Is the Better Value Stock Right Now?

The layoff trend has carried into 2023, and it isn't confined to the tech sector. French pharmaceutical producer Sanofi SA (NASDAQ: SNY ) has reported that it plans to let go of all staff at two vaccine plants based in India.

Sanofi Layoffs 2023: What to Know About the Latest SNY Job Cuts

Sanofi's (SNY) top line is likely to have been driven by higher sales of Dupixent and vaccines.

Can Sanofi (SNY) Keep the Beat Streak Alive in Q4 Earnings?

Expedia

IDEXX Laboratories

SolarEdge Technologies

Tradeweb Markets

Five Nasdaq Composite companies are set to beat earnings estimates. These are: EXPE, IDXX, SNY, TW and SEDG.

Top 5 Nasdaq Composite Stocks to Buy Ahead of Q4 Earnings

McKesson

There is a continued need for prosperous healthcare companies, here are two medical stocks investors may want to consider buying ahead of earnings this week.

2 Medical Stocks to Consider Buying Before Earnings

AstraZeneca

The court ruled that drugmakers can limit their shipments of federally-discounted drugs to pharmacies, in a blow to hospitals and clinics.

News for Sanofi Stock (SNY)